Navigation Links
Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent
Date:9/2/2014

treatment and formulation aspects of NB32, in the United States and certain foreign countries under the Patent Cooperation Treaty, or PCT. Use of a proprietary tri-layer NB32 tablet for weight loss is protected in the United States by U.S. patent numbers 8,088,786 and 8,318,788, which are expected to expire in February 2029 and November 2027, respectively. In addition, the dose escalation schedule of Contrave is protected by U.S. patent 8,722,085, which is expected to expire in November 2027. Orexigen has filed other patent applications in the United States and other parts of the world with the potential, if the patents issue, to extend intellectual property protection as late as 2034.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize NB32 in the United States. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements 
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential,"
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
8. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
9. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
10. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
11. Orexigen Receives CHMP Day 180 List of Outstanding Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... 10:00 CET, AMSTERDAM, February 20 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... full year 2007 results., Highlights - ... Cash & cash equivalents of EUR 51.3 million at June 30, ... AMT 011 - Positive results of Phase I/II in LPL ...
... new technologies launched onboard a U.S. Naval Academy satellite ... space. One technology is a sensor that can check ... "film" that can control heat. , These technologies were ... Md.; NASAs Ames Research Center, Moffett Field, Calif.; and ...
... a collaboration between researchers at the National Institute of ... of Kentucky potentially offers a low-cost way to mass ... sheets for a wide range of applications including flexible ... for field diagnostics. , In a paper posted this ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2007 2Amsterdam Molecular Therapeutics Reports Full Year Results 2007 3Amsterdam Molecular Therapeutics Reports Full Year Results 2007 4Amsterdam Molecular Therapeutics Reports Full Year Results 2007 5Amsterdam Molecular Therapeutics Reports Full Year Results 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 7NASA MidSTAR-1 successful technologies may be revolutionary 2NASA MidSTAR-1 successful technologies may be revolutionary 3NASA MidSTAR-1 successful technologies may be revolutionary 4Directed self-ordering of organic molecules for electronic devices 2
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... peculiarities with the DNA of just about every other plant ... as transposons, or "jumping genes," which have the ability to ... cell. An astounding 50% of human DNA ... former transposons that were active thousands to millions of years ...
... (Sept. 6, 2011) The American Physiological ... and the ENaC/Degenerin Family of Ion Channels, being held ... Grove, Calif. This scientific conference explores the connection ... growing global health concern. The five-day program ...
... surgeons are working together to improve the treatment of ... bone plates in the skull to fuse too soon. ... remove portions of the fused skull bones, and in ... -- requiring additional surgeries. Researchers in the Atlanta-based ...
Cached Biology News:A 'jumping gene's' preferred targets may influence genome evolution 2A 'jumping gene's' preferred targets may influence genome evolution 3Highlights of upcoming conference on aldosterone & the ENaC/Degenerin family of ion channels 2Developing technologies to improve the treatment of craniosynostosis in children 2Developing technologies to improve the treatment of craniosynostosis in children 3Developing technologies to improve the treatment of craniosynostosis in children 4
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Request Info...
Biology Products: